WALTHAM, Mass. – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Fermentas International Inc. With Fermentas’ broad range of high-quality molecular and cellular biology research tools, including reagents, enzymes and kits, Thermo Fisher can offer a complete workflow for genomics research while building on its platform of PCR and qPCR tools and resources.

Fermentas has approximately 500 employees, is headquartered in Burlington, Ontario, and has principal operations in Vilnius, Lithuania. The company had full-year revenues of approximately CAD $57 million in 2009 (approximately USD $55 million). Fermentas will be integrated into Thermo Fisher Scientific’s Analytical Technologies Segment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.

SOURCE: Thermo Fisher Scientific Inc.